Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

CTI BioPharma Corp. (CTIC)

4.3   0 (0%) 03-24 16:00
Open: 4.28 Pre. Close: 4.3
High: 4.34 Low: 4.22
Volume: 1,766,242 Market Cap: 567(M)

Technical analysis

as of: 2023-03-24 4:25:06 PM
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 5.9     One year: 6.52
Support: Support1: 4.19    Support2: 3.49
Resistance: Resistance1: 5.05    Resistance2: 5.59
Pivot: 4.48
Moving Average: MA(5): 4.35     MA(20): 4.71
MA(100): 5.42     MA(250): 5.53
MACD: MACD(12,26): -0.3     Signal(9): -0.3
Stochastic oscillator: %K(14,3): 8.3     %D(3): 11.3
RSI: RSI(14): 26.9
52-week: High: 7.8  Low: 3.31
Average Vol(K): 3-Month: 3,037 (K)  10-Days: 3,075 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ CTIC ] has closed above bottom band by 21.4%. Bollinger Bands are 32.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 4.35 - 4.37 4.37 - 4.39
Low: 4.17 - 4.19 4.19 - 4.21
Close: 4.27 - 4.3 4.3 - 4.33

Company Description

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.

Headline News

Sat, 25 Mar 2023
CTI BioPharma Sees Unusually High Options Volume (NASDAQ ... - MarketBeat

Fri, 24 Mar 2023
Incyte (INCY) Gets CRL for Jakafi Extended-Release Tablets - Nasdaq

Wed, 08 Mar 2023
Is CTI BioPharma Corp (CTIC) a Winner in the Healthcare Sector? - InvestorsObserver

Wed, 08 Mar 2023
CTI BioPharma Corp. (NASDAQ:CTIC) Q4 2022 Earnings Call Transcript - Yahoo Finance

Mon, 06 Mar 2023
After-Hours Earnings Report for March 6, 2023 : TCOM, NTNX ... - Nasdaq

Mon, 06 Mar 2023
CTI BioPharma: Q4 Earnings Snapshot - Torrington Register Citizen

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 132 (M)
Shares Float 122 (M)
% Held by Insiders 0.1 (%)
% Held by Institutions 81.8 (%)
Shares Short 13,500 (K)
Shares Short P.Month 12,730 (K)

Stock Financials

EPS -0.77
EPS Est Next Qtl 0
EPS Est This Year -1.26
EPS Est Next Year -1.88
Book Value (p.s.) -0.13
Profit Margin (%) -172.4
Operating Margin (%) -132.2
Return on Assets (ttm) -45
Return on Equity (ttm) 0
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0.38
Sales Per Share 0.4
EBITDA (p.s.) -0.53
Qtrly Earnings Growth 0
Operating Cash Flow -81 (M)
Levered Free Cash Flow -44 (M)

Stock Valuations

PE Ratio -5.59
PEG Ratio 0
Price to Book value -33.08
Price to Sales 10.5
Price to Cash Flow -6.99

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2017-01-02
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.